Tejaswini Kulkarni

13PUBLICATIONS
41CO-AUTHORS
Tissue engineeringMolecular targetsMedical mycologyAutoimmunityIntensive care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 31, 2026
Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study.

|Apr 03, 2026
Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases.

Tejaswini Kulkarni, Manuela Funke-Chambour, Steve Jones

|Nov 24, 2025
Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study.

Philip L Molyneaux, Nikhil A Hirani, Collin C K Chia

|Feb 19, 2025
TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity.

Huachun Cui, Sami Banerjee, Na Xie

|Jul 29, 2024
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial.

Tejaswini Kulkarni, Chad A Newton, Sachin Gupta

|Apr 16, 2024
Practice Patterns for Screening and Treating Interstitial Lung Disease-related Pulmonary Hypertension at Specialty Care Centers in the United States.

Sarah L Khan, Sonye K Danoff, Tejaswini Kulkarni

Pageof 3

Frequent Collaborators

2 joint publications

Nikhil A Hirani

2 joint publications

Philip L Molyneaux

1 joint publications

Fu Jun Li

1 joint publications

Joao A de Andrade